Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $454.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -17.37%
• EPS Growth: 52.28%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 381,995,120
• 10 Day Avg. Volume: 1,634,197
• 30 Day Avg. Volume: 1,385,775
• PEG Ratio: 0.10
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 3.54
• P/FCF Ratio: -4.07
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 4.02
• Enterprise Value/Ebitda: -2.65
• 1Y Price Target: $1.35
• Price Target Upside: -4.93% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $1.50 ▲(5.63% Upside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues and persistent losses. Technical analysis provides some positive momentum, but valuation concerns due to negative earnings and lack of dividends weigh heavily on the stock's attractiveness.

Positive Factors

Low Debt Levels

Maintaining low debt levels enhances financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant financial strain.

Strong Gross Profit Margin

A stable gross profit margin indicates efficient cost management and pricing power, which can support long-term profitability as revenue grows.

Strategic Partnerships

Strategic partnerships can drive innovation and expand market reach, enhancing the company's competitive position and potential for revenue growth.

Negative Factors

Declining Revenue

Declining revenue growth poses a challenge to sustaining operations and funding future growth, potentially impacting long-term viability.

Negative Cash Flow

Negative cash flow indicates potential liquidity issues, limiting the company's ability to invest in new projects or weather economic downturns.

Profitability Challenges

Ongoing profitability challenges can hinder the company's ability to reinvest in its business and compete effectively, affecting long-term growth prospects.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through the sale of its proprietary instruments, consumables, and software solutions. Key revenue streams include direct sales of lab equipment, such as the company's flagship products for single-cell analysis and multi-omics applications, as well as ongoing sales of consumable reagents required for these systems. The company also benefits from service contracts and maintenance agreements for its instruments. Additionally, Standard BioTools has established strategic partnerships with academic institutions, pharmaceutical companies, and research organizations, which can lead to collaborative projects, joint ventures, and potentially lucrative licensing agreements that further bolster its earnings.

Standard BioTools Financial Statement Overview

Summary

Standard BioTools is facing significant financial challenges with declining revenues and persistent losses. Despite a low debt level, the negative profitability and cash flow issues are major concerns, indicating a need for strategic improvements.

Income Statement

Standard BioTools has faced declining revenue with a negative growth rate of -16.48% in the TTM. The company is struggling with profitability, as indicated by negative net profit and EBIT margins. Gross profit margin remains relatively stable at 47.94%, but the overall financial performance is hindered by significant losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.069, indicating low leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a relatively strong equity position compared to its total assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting cash flow challenges. The free cash flow to net income ratio is above 1, indicating that free cash flow exceeds net income, but both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	128.83M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	61.76M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-93.61M	-118.14M	-54.46M	-173.57M	-44.27M	-34.60M
Net Income	-128.25M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	539.64M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	194.90M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	27.39M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	139.98M	140.62M	471.12M	471.78M	180.62M	185.71M
Stockholders Equity	399.66M	471.72M	-148.05M	-81.47M	94.60M	139.05M
Cash Flow
Free Cash Flow	-98.42M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-87.21M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	61.17M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.57M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.42 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.29, and above the 200-day MA of 1.22, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 60.92 is Neutral, neither overbought nor oversold. The STOCH value of 78.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$883.61M	14.41	24.11%	―	14.46%	―
FLGT	60 Neutral	$881.62M	―	-3.80%	―	13.60%	74.64%
CSTL	60 Neutral	$1.17B	―	-2.69%	―	10.15%	-295.52%
PSNL	57 Neutral	$952.87M	―	-43.69%	―	-21.02%	47.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	49 Neutral	$454.57M	-3.72	-24.63%	―	-17.37%	52.28%
MYGN	49 Neutral	$711.22M	―	-72.52%	―	0.21%	-233.51%

Standard BioTools Corporate Events

Standard BioTools Inc. Reports Q3 2025 Financial Results

Standard BioTools Inc., a prominent player in the biomedical research sector, specializes in providing next-generation technologies such as SomaScan, mass cytometry, and microfluidics to aid researchers in developing better medicines. The company recently reported its financial results for the third quarter of 2025, highlighting a total combined revenue of $46.2 million, with $19.6 million from continuing operations. The company is undergoing a significant restructuring plan aimed at achieving over $40 million in annualized cost savings, setting a path towards positive adjusted EBITDA by 2026.

Standard BioTools Implements Restructuring for Future Growth

Standard BioTools reported a third-quarter 2025 revenue of $19.6 million from continuing operations, marking an 11% decline year-over-year. The company has implemented a restructuring plan expected to save $40 million annually, with a goal of achieving positive adjusted EBITDA by 2026. The restructuring includes a 20% workforce reduction and consolidating operations to improve efficiency. The company anticipates a significant cash boost from a pending transaction with Illumina, which will support its growth strategy through mergers and acquisitions.

The most recent analyst rating on (LAB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces Workforce Reduction Plan

On September 13, 2025, Standard BioTools Inc. initiated a restructuring plan, which includes a 15% reduction in its global workforce. This move aims to enhance operational efficiency and align costs with revenue projections, supporting the company’s long-term strategic goals. The restructuring is expected to incur expenses of approximately $7.5 million, primarily for severance and termination benefits, with potential for additional unforeseen costs.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces Strategic Restructuring Plan

On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard Biotools Inc. Faces Challenges in SomaScan Divestiture: Potential Risks and Strategic Imperatives

Standard Biotools Inc. faces significant risks in realizing the anticipated benefits from its recent Transaction, particularly if it fails to divest the SomaScan Business. The company may encounter material adverse effects such as management distraction, employee loss, and challenges in managing the divestiture, which could hinder cost savings and impact financial performance. These issues, largely beyond the company’s control, could lead to increased costs, reduced revenues, and a potential decline in stock market value, thereby affecting its overall business prospects. Such risks underscore the importance of effective management and strategic planning to mitigate potential negative outcomes.